NDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CHIBROXIN (norfloxacin) by Merck & Co.. Approved for bacterial infections, diarrhea, pneumonia. First approved in 1991.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHIBROXIN is a fluoroquinolone antibiotic (norfloxacin) approved in 1991 as an ophthalmic solution for treating bacterial eye infections, including conjunctivitis and corneal ulcers. Administered as topical drops, it works by inhibiting bacterial DNA gyrase to exert bactericidal activity against gram-positive and gram-negative pathogens.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30/100), indicating a shrinking brand team and shift toward generic or brand-defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on CHIBROXIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.